14th Mar 2007 11:00
ABCAM Plc14 March 2007 For immediate release 14 March 2007 ABCAM PLC ("Abcam" or "the Company") Appointment of Commercial Director Cambridge UK, 14 March 2007: Abcam plc (AIM: ABC), the rapidly growingbioscience company that markets antibodies via its own online catalogue, ispleased to announce that Mark Webster, who joined the Company as a Non-ExecutiveDirector in July 2006, has been appointed to the executive position ofCommercial Director. This newly created position, in which Mr Webster will have overallresponsibility at Board level for sales, marketing and business development, hasbeen formed in response to the Company's rapid growth both in the UK andinternationally. Mr Webster brings significant experience of sales and marketingin Abcam's biggest market, the US, where he will have the job title ExecutiveVice President Sales & Marketing. Mr Webster, age 45, is a highly experienced pharmaceutical executive who hasheld senior management positions, with an emphasis on international sales andmarketing, at Bayer, Shire Pharmaceuticals and Abbott Laboratories. His mostrecent executive position was Senior Vice President, Head of Global StrategicMarketing and Licensing/Acquisitions at Bayer Pharmaceuticals. Commenting on today's announcement, David Cleevely, Abcam's Chairman, said: "Since joining Abcam last year as a Non-Executive Director, Mark has made a veryvaluable contribution to the Board in terms of his input on sales and marketingstrategy. I am delighted that he has agreed to take the executive position ofCommercial Director, a role that we believe will be of significant strategicimportance in the management of the Company's rapid growth." Mr Webster has today been granted, under the Abcam 2005 Share Option Scheme,options over 167,230 ordinary shares of 1p each in the capital of the Company atan exercise price of 296p. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerEddie Powell, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7776 1500Michael MeadeJames Black Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors: About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcamwas admitted to AIM in November 2005 and trades under the ticker symbol ABC.The Company produces and distributes its own and third party produced antibodiesto academic and commercial users throughout the world with product informationprovided and ordering available through the Company's website, www.abcam.com.The antibodies are sold under the Abcam brand name. The Company's vision is tobuild the largest online antibody resource in the world while also ensuring thatthe antibodies are of high quality and commercially viable. Abcam now has anonline catalogue of approximately 29,000 products, most of which are antibodies,from over 200 suppliers supported by up-to-date and detailed technical datasheets, which are created by the Company. The Company currently employs 120staff in its three operating companies. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
ABC.L